How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?

Complex modalities can present different challenges with manufacturing, whether at a CDMO or in-house. For a CDMO, it’s important to maintain flexibility in the types of products that can be produced on a given line. This presents the greatest number of potential projects and supports consistent utilization of manufacturing lines, facilities, and staff. However, there is not one manufacturing line for all modalities and scales, despite the combi-equipment available on the market today (e.g., a single line with capabilities to fill-finish vials, syringes, and cartridges).

The reason is that certain products and/or modalities typically require dedicated equipment and, in some cases, dedicated facilities. CDMOs can then differentiate based on modality or class of products, the phase of development, and the scale at which they can deliver. Alcami’s sterile drug product manufacturing, as an example, is ideal for both biologics/large molecules (mAbs, oligos, bispecifics antibodies) and small molecules with occupational exposure limits (OELs) > 0.03 ug/mL.

Each fill-finish line at Alcami is supported by regulatory and quality systems for both clinical and commercial production. Lastly, Alcami’s scale of production ranges from 1,000-unit phase I studies to more than one million (or millions of) annual units to support commercial supply.

Potent substances make up an increasingly large proportion of development pipelines, as advanced therapies for the treatment of cancer continue to expand, and targeted modalities such as antibody–drug conjugates (ADCs) demonstrate their utility in 'treating the untreatable.' However, 'highly potent' refers to a scale of potency, so ESTEVE CDMO has incorporated specialized and flexible handling within its sites to ensure it can provide partners with the handling and processing capabilities that they need, both now and in the future, while simultaneously ensuring the safety of its employees.

As modalities become more complex, CDMOs are increasingly required to differentiate through specialized containment capabilities and the ability to manage highly potent compounds across development and manufacturing scales. This is also driving greater reliance on complementary technologies that help address well-known development challenges, such as stability, poor solubility, potency, and scalability. In parallel, investment across the sector is focused on strengthening infrastructure to support these requirements. For instance, ESTEVE CDMO is expanding production capacity and spray drying capabilities within purpose-built high-potency containment suites in Celrà, Spain, aligned with the need to support increasingly complex pipelines from development through to commercial scale.

ESTEVE CDMO currently operates dedicated high potency containment facilities at its Banyeres del Penedès manufacturing site and is actively expanding capacity at its Celrà facility, including advanced high potency containment suites with spray drying capabilities, to support increasingly complex pipelines from development through to commercial scale.

The explosion of complex modalities is reshaping the development and manufacturing landscape, prompting many traditional small molecule CDMOs to reassess how they create value. Differentiation is no longer about broad capability, but about owning the highest-barrier, high-risk steps in these emerging modalities. Areas such as highly potent active pharmaceutical ingredient (HPAPI) synthesis, ADC payload development, and advanced linker chemistry continue to demand specialized expertise and high containment infrastructure, capabilities that remain concentrated among a relatively small group of providers.

Sponsors are looking for CDMOs to seamlessly integrate payloads into ADCs while also supporting adjacent modalities, including the supply of lipid components and modified nucleosides for RNA therapies and lipid nanoparticle (LNP) systems. This ability to bridge small molecule chemistry with hybrid modalities is becoming a key point of differentiation. Traditional small molecule providers without these capabilities are increasingly unable to compete effectively in this space.

High containment environments designed for ultra potent compound handling featuring engineering controls such as advanced HVAC systems, closed transfer technologies, and enhanced personnel protection, are increasingly essential for safe, compliant scale up. Wilmington PharmaTech has the capabilities in place to not only mitigate occupational exposure risks but also support a robust, auditable, and regulatory-compliant manufacturing environment.

CDMOs differentiate themselves by demonstrating the specific value they can create, and much of that differentiation is tied to the modalities they are equipped to support. Sponsors expect their partners to bring deep, modality relevant expertise and the ability to execute reliably, so CDMOs continually highlight the technical capabilities and experience that set them apart from competitors.

For emerging modalities, such as cell and gene therapies or RNA platforms, sponsors are looking for CDMOs that can navigate evolving regulatory pathways, design development strategies, and anticipate scale up challenges. Only a subset of CDMOs possess the scientific and regulatory depth required to guide programs from early development through approval, creating a clear basis for specialization.

Even in more established areas such as ADCs, bispecifics, and HPAPIs, handling complexity safely and efficiently requires dedicated infrastructure, containment strategies, and experienced teams. Mid tier CDMOs often excel here, using focused expertise to offer tailored solutions that larger, generalized organizations may struggle to match.

Rather than fundamentally changing CDMO strategy, the rise of complex modalities is amplifying an existing trend: differentiation through specialization. CDMOs that articulate clear focus areas and build modality aligned development frameworks are best positioned to help sponsors meet aggressive timelines, manage regulatory risk, and advance increasingly sophisticated therapies.

Different modalities bring fundamentally different challenges, and there is no universal solution. Each requires its own specialized infrastructure, distinct scientific expertise, and a tailored development philosophy. A containment suite engineered for HPAPIs looks nothing like a peptide synthesis platform, and neither resembles the conjugation chemistry and heterogeneity analytics demanded by ADCs. Trying to serve these modalities without purpose-built capabilities is a disservice to sponsors and their programs.

At BioDuro, we've made deliberate investments in the areas where complexity is highest and the margin for error must be lowest. Across HPAPIs, ADCs, and peptides, we've built integrated capabilities spanning chemistry, biology and drug metabolism and pharmacokinetics (DMPK), streamlining drug discovery while keeping the science connected, the data coherent, and critical insights intact rather than lost in handoffs. As we continue expanding our chemistry, manufacturing, and controls (CMC) capabilities, we remain committed to helping innovators advance with confidence from discovery to development and beyond.

That end-to-end integration across genuinely specialized platforms is where we believe meaningful CDMO differentiation lies, not in claiming to do everything but in doing the hardest things exceptionally well.

Complex modalities are reshaping the CDMO landscape. Therapeutic modalities, such as ADCs, bispecifics, RNA therapies, and next-generation antibody conjugates, require far more than standalone production capabilities. They demand deep process understanding, advanced analytical strategies, effective technology transfer, and close integration across development, manufacturing, quality, and supply chain functions. This is why strong technical teams are playing an increasingly critical role.

For ADCs, CDMOs must bridge biologics manufacturing with high-potency chemistry, conjugation technologies, and analytical control strategies while ensuring process robustness and commercial scalability. Similarly, as technologies evolve, emerging RNA and engineered antibody platforms require technical teams that can rapidly build process knowledge while also managing platform adaptability and efficient life cycles.

Clients are therefore selecting CDMO partners based not only on infrastructure but also on the strength of their technical organizations and collaborative ability to solve complex manufacturing challenges efficiently. In this environment, differentiation will come from teams that combine scientific depth, operational agility, and cross-functional leadership to accelerate innovative therapies from development to commercial supply.

The increasing complexity of therapeutic modalities is fundamentally reshaping the role of CDMOs across the industry. HPAPIs, ADCs, cell and gene therapies, and other advanced technologies, such as oligonucleotides and mRNA, require much more than manufacturing capacity alone. These programs demand specialized scientific expertise, deep process knowledge, and the ability to navigate increasingly complex development and regulatory requirements.

As biopharma continues to advance toward more targeted and technically sophisticated therapies, CDMOs have evolved into indispensable innovation partners. We are seeing growing demand for CDMOs that can provide integrated development and manufacturing support across the full program life cycle. For example, reducing operational handoffs and maintaining continuity of product, along with process knowledge can have a significant impact on speed, efficiency, and overall program execution.

At the same time, digitalization, automation, and AI-supported process optimization are becoming industry-standard solutions for enhancing compliance and operational efficiency within highly complex manufacturing environments.

The industry continues to evolve quickly, and CDMOs must evolve with it. The organizations that will stand out are those able to combine technical depth, operational flexibility, and strong scientific collaboration while adapting alongside the rapid pace of innovation occurring across advanced therapeutics.

As modalities become more complex, CDMO differentiation is shifting from individual technical capabilities to the ability to keep programs moving across the full development and supply pathway.

For many advanced modalities, the biggest risks do not always come from the science itself. They often emerge at the handoffs: from development to GMP manufacturing, from manufacturing into clinical trial supply, and from clinical-scale production to commercial readiness. Each transition introduces operational, regulatory, analytical, supply chain, and data challenges that can slow momentum if they are not well coordinated.

As a result, specialization is evolving. It is no longer enough for a CDMO to be known for a specific platform, technology, or manufacturing capability. The stronger differentiator is the ability to connect development, manufacturing, clinical trial supply, data flows, and commercial delivery into a coherent operating model.

CDMOs that can support a program as it progresses, anticipate complexity before it becomes a bottleneck, and reduce friction between stages are increasingly better positioned. In that sense, the ability to carry complex programs forward without losing speed, quality, or control is becoming a more meaningful source of differentiation than any single capability on its own.

The rapid rise of complex modalities is raising the bar for CDMO differentiation. The focus is no longer on capacity or cost alone, but on the ability to systematically de-risk development and industrialize complexity — from discovery through CMC, tech transfer, and commercial supply. Across the industry, we see growing demand for complex antibodies, conjugates, and advanced therapies that require domain expertise, dedicated technologies, and strong cross-functional integration.

We believe the winning model is an integrated, end-to-end CRDMO platform that combines deep specialization with seamless execution. Rather than managing multiple partners, innovators need a single partner with proven experience in complex modalities and the ability to advance programs efficiently with fewer handoffs. This shift is reflected in our integrated projects: in 2025, we added 209 new integrated projects, with two-thirds in complex biologics. This underscores a broader trend — particularly for complex modalities, the efficient pipeline advancement increasingly depends on specialized, integrated CRDMO capabilities.

At the same time, complexity is redefining what service means. Flexibility and agility are becoming critical, as advanced therapies are often marked by variable demand and evolving processes. This requires not only scalable, right-sized manufacturing solutions, but also flexible service models and accelerated development timelines — for example, enabling CMC development for complex molecules such as bispecific antibodies in as fast as six months. Digitalization capabilities are becoming a key differentiator — enabling better process insight, faster decision making, and more reliable manufacturing.

Ultimately, CDMOs that combine technical depth, integrated solutions, and digital capabilities will be best positioned to make scientific complexity more predictable and deliverable, translate innovation into accessible therapies for patients.

As drug pipelines expand beyond conventional small molecules and standard biologics, CDMOs are being pushed to define themselves through narrower, higher-value areas of expertise. Modalities such as HPAPIs, ADCs, bispecific antibodies, cell and gene therapies, and RNA-based medicines do not rely on a common manufacturing playbook; each brings its own process requirements, control strategies, analytical challenges, and facility demands. In the past, service providers could position themselves primarily on the basis of chemical versus biological manufacturing. That distinction is becoming much less useful because many emerging therapies sit at the intersection of both. ADCs are a clear example: they require biologics manufacturing capabilities alongside potent compound handling, linker chemistry, bioconjugation expertise, and advanced characterization techniques. The same pattern appears across other platforms, where chemistry, biology, and specialized GMP operations increasingly need to work together. This is making broad, multi-modality depth difficult to sustain within a single organization. As a result, CDMO differentiation is shifting toward targeted platform leadership, selective capital investment, and demonstrated excellence in the specific modalities where a provider can offer truly differentiated expertise.

As cell and gene therapies mature, it is clear that not every CDMO is equipped for their complexity. CGT manufacturing is not an extension of traditional biologics because it requires a fundamentally different operating model built around vein-to-vein execution, rigorous chain-of-identity control, and real-time digital coordination. When each batch represents a patient, precision and reliability are non-negotiable.

Capacity expansion alone will not solve the challenges of variability, logistics, and commercialization. True differentiation lies in purpose-built infrastructure, standardized platforms, and deep CGT expertise. In this space, specialization is not a competitive edge but is the prerequisite for delivering patients’ therapies reliably and at scale.

The rise of complex modalities is forcing CDMOs, particularly smaller ones, to specialize rather than try to be all things to all people. The market increasingly rewards deep expertise in a specific niche. A telling example is Ajinomoto's acquisition of Forge Biologics, which succeeded precisely because of Forge's focused specialization in in vivo gene therapies.

The next wave of investment is moving toward in vivo cell modification, delivering a vector directly into a patient to modify T cells internally, rather than the traditional ex vivo approach of extracting, engineering, and reinfusing them. CDMOs that can position themselves ahead of that curve stand to win significant business.

But that specialization carries real risk. Building capacity for an emerging modality before demand is fully validated is high stakes bet. "If I build it, they will come" is not a guaranteed outcome. The key is reading the tea leaves: understanding what you're genuinely good at and where science is heading and aligning those two things before the window closes.

The increasing complexity of modalities is reshaping the pharmaceutical industry in many ways, and one important point is the pressure on quality control. I speak from a CRO (contract research organization) perspective, having spent over two decades developing and validating GMP-compliant testing for biologics, from conventional vaccines to recombinant proteins and to cell and gene therapy products. The manufacturing challenges of those new therapies are real, but what we observe is the need for strong support around navigating stringent regulatory frameworks and the evolution of their analytical programs around those new product types.

When a manufacturer brings a lentiviral vector, a CAR-T starting material, or an RNA-based construct, the biosafety and characterization package is very different from a monoclonal antibody program. Adventitious agent testing strategies have to be rethought. Identity assays require a level of molecular resolution that many existing quality programs were simply not designed to provide. Regulatory guidelines are also evolving, for example the integration of NGS (next-generation sequencing) into ICH Q5A(R2), was a significant step forward, it is the recognition of a key innovation for a stronger viral safety to replace certain in vivo tests. Characterization faces the same evolution, demonstrating potency and knowledge of the drug product quality for a cell therapy or a viral vector means developing advancing assays with specific designs.

Competitive biotechs, pharmas, or CDMOs are those who carefully think about integrating or partnering with the right CRO with specialized expertise to translate new regulatory expectations and innovative technologies.

What is becoming clearer, at least from our point of view, is that strong program architecture is replacing a service menu model. Manufacturers now ask their QC (quality control) partners more than just a list of available tests. They need an organization that can support their full quality program, from cell banking through lot release, with strong regulatory knowledge to help them design the right path for filing. Getting there requires cautious choices about where to invest and what test to develop and who to partner with.

As therapeutic modalities become increasingly complex, CDMOs are moving away from standardized, one-size-fits-all manufacturing models toward more specialized and modality-specific manufacturing strategies.

Differentiation is becoming less about broad platform capabilities and more about deep process understanding. Advanced therapies place fundamentally different demands on downstream development, and success increasingly depends on how effectively purification strategies can be tailored to the unique characteristics of each molecule. This is particularly important for biomolecules that do not behave like conventional biologics, where process fit can directly influence product quality, recovery, and scalability.

For Astrea Bioseparations, this shift reinforces the growing importance of fit-for-purpose purification technologies for complex biomolecules. In larger viral vector modalities especially, legacy technologies are not always well aligned with the size, fragility, and impurity profile of the target. Technologies such as AstreAdept^® nanofiber are therefore becoming increasingly relevant, offering an open flow path, highly accessible binding surface area, and a gentler processing environment that can better support efficient and scalable purification. In this context, specialization is becoming a defining factor in CDMO competitiveness. The ability to combine modality-specific expertise with scalable purification technologies will increasingly shape how CDMOs differentiate themselves, deliver technical value, and build long-term partnerships within the biopharmaceutical industry.

New drug modalities are an expanding class of therapeutic approaches that go beyond traditional small molecules and biologics. This implies new molecule types, but also new routes of administration and associated formulation challenges. Innovative platforms leveraging various mechanisms are thus needed to achieve targeted and efficient disease treatment.

CDMOs are key partners for the development and industrialization of innovative modalities, but as these molecules are highly diverse and present very specific and complex formulation challenges, these players may find themselves facing a strategic positioning dilemma.

Indeed, a generalist positioning does not meet today’s market’s need for expertise. An expert/niche positioning focused on a specific family of modalities limits visibility and makes the business plan riskier. A partnership strategy, involving a network of experts in the formulation of these modalities, each with specific expertise, may be the most appropriate strategy, allowing to offer a wide range of expert solutions to customers.

At Gattefossé, we are actively involved in this way by offering our CDMO partners our expertise in lipid formulations for new modalities: we support them in overcoming the challenges they face, particularly regarding bioavailability.

Increasing modality complexity, in particular in cell and gene therapy (CGT), is redefining CDMO differentiation. The success of CGT modalities will depend on capabilities that can improve reproducibility and lower cost of goods (COGs). For example, in gene therapies, differentiation is shifting from adding bioreactors to mastering vector-native science and translating it into reliable, scalable operations.

For AAV, and increasingly LVV, CDMOs are institutionalizing platformed yet flexible processes: upstream intensification and optimized transfection chemistry; stable producer lines and high-productivity cell banks; and serotype-specific downstream workflows that balance yield, purity, and full-to-empty control. Successful CDMOs embed comprehensive vector analytics into CQA-driven control strategies, paired with adventitious agent mitigation and rapid, orthogonal release methods, and deploy automated, digitalized unit operations and electronic batch records to cut variability, accelerate tech transfer, and enable real-time visibility. 

For cell therapies, differentiation hinges on translating scientific nuance into operational excellence across autologous and allogeneic models. CDMOs are focused on platformizing with modular, single-use suites that enable rapid tech transfer while retaining flexibility for cell type and indication; embedding rapid, in-line analytics and fit-for-purpose potency assays and applying automation and AI-driven process control to reduce deviations and COGs. Purpose-built quality systems, robust training, and hardened supply chains, and strategic partnerships complete the model. Ultimately, sustained investments in scientific depth, digital and quality infrastructure, and regulatory expertise create differentiation that cannot be easily replicated.

The increasing complexity of cell therapy is enabling greater CDMO specialization that creates value beyond pure manufacturing capacity. Success in cell therapy increasingly depends on the integration of process development, analytics, manufacturing, regulatory strategy, and clinical execution. As global competition intensifies in China, development speed, capital efficiency, and scalability are critical differentiators. Biotechnology companies can progress faster by partnering with organizations with accumulated translational experience to avoid repeating lessons already learned across the field.

At CTMC, we believe integrated translational models are uniquely fit-for-purpose for cell therapy. The value is operational efficiency, but also the ability to apply experience gained across multiple programs, investigational new drugs (INDs), regulatory interactions, and clinical translations proactively rather than rediscovering those lessons company by company. One example is our close integration with UT MD Anderson Cancer Center, which allows us to significantly compress timelines between IND clearance and clinical site activation by aligning manufacturing, regulatory, and clinical readiness much earlier in development, which is difficult to achieve within a more traditional sponsor–CDMO–clinical site relationship. This creates an opportunity for CDMOs to work alongside sponsors in an integrated way, resulting in reduced execution risk, improved capital efficiency, accelerated development timelines, and therapies positioned for long-term commercial scalability and success.

The rapid rise of complex modalities — HPAPIs, ADCs, bispecifics, cell and gene therapies, and RNA-based therapies — is reshaping how CDMOs differentiate globally.

Compared with small molecules and monoclonal antibodies, cell and gene therapies and RNA-based therapies are exposed to greater manufacturing, analytical, and regulatory complexities. CDMOs must move beyond scale-driven models toward modality-specific expertise and solutions. Success depends on robust process development, advanced analytics and characterization, reliable tech transfer, and tightly controlled GMP execution. Importantly, the commercial viability of cell therapies largely depends on effective cost reduction strategies including availability of automation solutions built into the clinical development and commercial launch strategy.

Emerging innovations, such as in vivo CAR T delivery, further raise technical requirements, demanding sophisticated engineering, data-driven scale-up, and risk-mitigating development models. CDMOs, such as Lonza, are responding by embedding advanced analytics and GMP-focused process development early to de-risk scale-up and commercialization. Differentiation increasingly depends on offering end-to-end clinical and commercial manufacturing, supported by platform technologies that shorten timelines and support consistent GMP-compliant operations. For example, AAV gene therapies can benefit from stable producer cell line platforms which are designed to improve titer, robustness, and scalability, which can lead to reduced complexity, enhanced product quality, and lower COGS.

A global footprint is also becoming increasingly important in today’s environment. CDMOs with a global model can help developers transition emerging modalities from restricted, high-cost treatments to widely, standardized care worldwide. In parallel with expected market growth, global capacity can expand patient access, reduce logistical bottlenecks and costs, and enable harmonized quality oversight across regions.

Ultimately, modality complexity is pushing CDMOs to prioritize depth over breadth by investing in specialized infrastructure, talent, and analytics while supporting multiple modalities under one roof. This shift positions differentiation around risk reduction, scalability, and long-term partnership rather than capacity alone.

The biopharmaceutical landscape is undergoing a profound shift. As therapeutic modalities advance from single-mutation targets to complex, next-gen platforms such as advanced cell and gene therapies (CGTs) and RNA therapies, the historical "one-size-fits-all" CDMO model is no longer viable.

I see this complexity fundamentally reshaping how CDMOs must differentiate and specialize. The market is moving away from generic capacity toward highly specialized, technology-driven platforms that solve specific biological and manufacturing bottlenecks.

As modalities become more advanced, regulatory and safety scrutiny intensifies. Traditional plasmid manufacturing, typically used as the DNA starting material for many of these therapies, introduce unwanted by-products like bacterial backbones or antibiotic resistance genes, alongside fermentation impurities, which may lead to safety risks.

CDMO specialization is therefore shifting toward "cleaner" manufacturing technologies. Working with a DNA provider that can design and create synthetic DNA templates that contain solely the target sequence ensures that bacterial impurities are never amplified in the first place. This allows for the precise generation of specific DNA shapes, like our fully-covalently closed hpDNA for viral vector applications, or partially closed opDNA developed for mRNA.

Additionally, upstream supply of high-quality DNA is currently one of the biggest bottlenecks for CDMOs. Whether for mRNA vaccines or gene-modified cell therapies, every program starts with DNA, and early-stage delays cascade severely downstream.

Conventional plasmid-based workflows add months to development timelines due to the lengthy requirements of cloning, linearization, purification, and long queue times. True differentiation for a CDMO requires compressing these timelines. By utilizing a cell-free, isothermal enzymatic process (such as 4basebio’s DNA), specialized CDMO partners can begin to differentiate themselves in a growing competitive landscape.

The hard problems of how a molecule is preserved, stabilized, and delivered have moved farther upstream, which has put a microscope on formulation depth rather than on scale or footprint. With so much modality complexity, sponsors want a formulation partner earlier in development, not just at fill-finish. This is driven by the fact that there are an increasing number of types of drugs, such as small molecules, proteins, biologics, and cell and gene therapies, each with its own problem statements that need to be addressed early. CDMOs have long sought to position themselves as partners who offer valuable counsel alongside excellent execution, and those that have invested in this approach have established themselves as the true experts to work with. For example, pharma CDMOs with cross-disciplinary backgrounds in discovery, preclinical development, formulation, engineering, dosage form expertise, and regulatory expertise can identify and mitigate downstream issues that may not be obvious to many generalists.

The growing complexity of new therapeutic approaches, especially ADCs, bispecifics, and cell and gene therapies, is accelerating a shift toward more specialization within the CDMO sector. These therapies demand higher standards for containment, sterility, formulation, and analytical testing while also elevating regulatory requirements for process control, specialized equipment, and quality assurance. This trend emphasizes the need for strong quality systems and operational flexibility. CDMOs with specialized technical skills and the ability to collaborate closely and flexibly with customers are better able to tackle complex development challenges and help build a successful pathway to commercialization.

Specialized expertise within specific modalities or manufacturing areas rather than broad, generalist skills, is essential. Customers are focusing on working with CDMOs as partners with proven experience in addressing the unique challenges of their therapeutic platforms, along with specialized equipment and the technical expertise to reliably manufacture these increasingly complex products at scale, always with an emphasis on quality.

This trend is especially pronounced in sterile injectables, where fill/finish has become a critical determinant of product performance, impacting stability, delivery, and clinical success. As formulations grow more complex, such as high-viscosity biologics and long-acting injectables, manufacturing success depends on a deep understanding of fluid dynamics, delivery systems, and process control to achieve consistent results at scale.

CDMOs that combine specialized technical expertise, fit-for-purpose equipment, and the ability to work closely and flexibly with customers are increasingly well-positioned to successfully navigate complex development and manufacturing challenges.

If there's one message we work hard to reinforce, it's that drug delivery cannot be an afterthought. Research and development teams naturally focus on the molecule itself, specifically payload, target, and mechanism. But a drug isn't a drug until you can administer it in a way that's stable, controlled, effective, and safe.

Most new advanced modalities simply can't be dosed “naked.” Nucleic acids are the clearest example. An unprotected mRNA- or oligo-based payload will be rapidly cleared in vivo. Even proteins and biologics can be fragile, immunogenic, or quickly degraded. Delivery isn't a downstream consideration; it determines whether a therapeutic concept can become a clinical reality.

Increasingly complex therapies inherently demand sophisticated delivery strategies. We began building Phosphorex over 20 years ago to provide the needed integrated expertise in particle-based delivery, specifically LNPs, polymeric nanoparticles, and polymeric microspheres. Our clients are typically biotech companies developing nucleic acid medicines, targeted therapies, or long-acting injectables, and they need the extensive drug delivery expertise we provide.

Innovators come to us because we've already solved the scale-up problems and understand how formulation decisions made at the bench must translate to clinical and ultimately commercial manufacturing. When a delivery strategy is designed from the start with scalability, reproducibility, and regulatory expectations built in, programs move faster and are much more likely to succeed. But to achieve this success, clients nearly always need our specialized drug-delivery expertise.

Cell therapies are becoming increasingly complex, and global regulators' expectations are rising, so CDMOs not built specifically for these changes are struggling to keep up. That's reshaping the market in ways that feel pretty permanent to me.

Cell therapy is not a single modality; it's a collection of them. For example, autologous programs operate on fundamentally different timelines and infrastructure requirements than allogeneic programs. In addition, today’s pipeline includes many different types of cell therapies. CAR-T, CAR-M, and CAR-NK therapies, TCR-T programs, differentiated iPSC-derived products, and regulatory T cell therapies all have distinct manufacturing processes, release requirements, and regulatory expectations that a generalist CDMO simply isn't well equipped to handle.

What we're seeing now is that depth of expertise is winning. Sponsors at the pivotal and commercial stages need a partner that has internalized the specific demands of their modality. For Kincell, that means focusing our resources on leading science and technologies to support cell therapy processes and building infrastructure that reflects how these programs actually progress through clinical development and into commercialization. Our Research Triangle Park facility expansion, which includes additional cleanrooms, a new MSAT and microbiology laboratory, additional GMP storage, and other investments, reflects Kincell’s commitment to channeling our resources to meet our customers’ needs as they increasingly move toward commercial licensure.

The market will not become less complex. Specialized, focused CDMOs are critical resources for leading emerging areas of the life sciences industry.

The rapid increase in modality complexity is fundamentally changing what differentiation means in the CDMO sector. It is clear that complexity is no longer the exception — it’s the rule. Developing complex modalities places unprecedented demands on development strategy, analytical depth and manufacturing control. As a result, CDMOs are being forced to rethink whether breadth or depth truly delivers value.

We’re seeing a clear shift away from generalist models toward deliberate specialization. Each modality brings distinct requirements, be that chemistry, analytical or processing expertise. Sponsors are choosing partners based on proven experience in working within specific modalities, not on the length of a service menu.

At Almac Sciences, our differentiation lives in enabling complex programs, rooted in small‑molecule and peptide expertise, but applied to many other modalities. The cultural and operational embedding of process and analytical development activities is applied to new modalities. For example, Almac has recently delivered enzymatic ligation process for oligo manufacture. Existing expertise in developing enzymatic reactions, combined with process and analytical method development capabilities, particularly for biomolecules, has been combined to successfully deliver in a new product class.

New modalities will often require reassessment of techno-regulatory topics. Traditional boundaries, scientific judgement and problem‑solving maturity, not just technology ownership. The most effective partners are those who are clear about where they add the greatest value and invest deeply to do those things exceptionally well. The focus, therefore, has become a strategic advantage — specialization is no longer optional.